


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nemolizumab for treating prurigo nodularis ID6451

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Galderma (nemolizumab) Patient/carer groups	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Changing Faces	Wales
Eczema Outreach Support	British National Formulary
Let's Face It	Care Quality Commission
National Eczema Society	Department of Health - Northern Ireland
Prurigo Nodularis International	Healthcare Improvement Scotland
South Asian Health Foundation	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
11	National Association of Primary Care
Healthcare professional groups	National Pharmacy Association
British Association of Dermatologists British Dermatologists	NHS Confederation Control Madicines Control Minimum
British Dermatological Nursing Group British Corieties Society	Scottish Medicines Consortium
British Geriatrics Society British Society for Cutopoous Allergy	Welsh Government Welsh Health Specialized Services
British Society for Cutaneous AllergyPrimary Care Dermatology Society	Welsh Health Specialised Services Committee
 Primary Care Dermatology Society Royal College of General Practitioners 	Committee
 Royal College of Nursing 	Possible comparator companies
Royal College of Pathologists	Advanz Pharma (methotrexate)
Royal College of Physicians	Aspen (azathioprine)
Royal Pharmaceutical Society	Bristol Myers Squibb (thalidomide)
Royal Society of Medicine	Cipla UK (methotrexate)
St John's Institute of Dermatology	Dexcel pharma (ciclosporin)
UK Clinical Pharmacy Association	Hospira (methotrexate)
,	Medac (methotrexate)
	Morningside Healthcare (methotrexate)
<u>Others</u>	Mylan (azathioprine; ciclosporin)
Department of Health and Social Care	Nordic Pharma (methotrexate)
NHS England	Nova (azathioprine)
	Novartis Pharmaceuticals (ciclosporin)
	Orion Pharma (methotrexate)



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	 Rosemont Pharmaceuticals (methotrexate) Sandoz (methotrexate) Santen UK (ciclosporin) Strides Pharma (azathioprine) Tillomed Laboratories (azathioprine) Zentiva (thalidomide)
	 Relevant research groups British Skin Foundation Centre of Evidence-based Dermatology, University of Nottingham Cochrane Skin Group Dermatrust Genomics England MRC Clinical Trials Unit National Institute for Health Research
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of nemolizumab for treating prurigo nodularis ID6451 Issue date: July 2024





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.